Article Versions Notes

Tünbekici S, Yuksel Hc, Acar C, Sahin G, Orman S, Majidova N, Coskun A, Seyyar M, Dilek Ms, Kara M, et al. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study. Cancers. 2025; 17(1):46. https://doi.org/10.3390/cancers17010046

Tünbekici, Salih, Haydar cagatay Yuksel, Caner Acar, Gökhan Sahin, Seval Orman, Nargiz Majidova, Alper Coskun, Mustafa Seyyar, Mehmet sıddık Dilek, Mahmut Kara, and et al. 2025. "Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study" Cancers 17, no. 1: 46. https://doi.org/10.3390/cancers17010046

Tünbekici, S., Yuksel, H. c., Acar, C., Sahin, G., Orman, S., Majidova, N., Coskun, A., Seyyar, M., Dilek, M. s., Kara, M., Dıslı, A. K., Demir, T., Kolkıran, N., Sahbazlar, M., Demırcıler, E., Kuş, F., Aytac, A., Menekse, S., Yucel, H., ... Gürsoy, P. (2025). Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study. Cancers, 17(1), 46. https://doi.org/10.3390/cancers17010046